RefleXion Medical is a medical technology company that enhances the use of radiopharmaceuticals in cancer treatment. Their SCINTIX® biology-guided radiotherapy system represents a significant advancement in targeting lung and bone tumors by automating treatment processes and managing motion during therapy. Designated as an FDA Breakthrough Device, SCINTIX therapy aims to revolutionize the way metastatic diseases are treated. By collaborating with top radiopharmaceutical companies, RefleXion is also involved in the development and commercialization of disease-specific radiotracers intended for late-stage cancer treatment. The company prioritizes innovative solutions in radiation oncology to improve patient outcomes, guided by a commitment to quality, safety, and excellence in clinical practice.